HTG Molecular Diagnostics, Inc.

Equities

HTGMQ

US40434H3021

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 11:15:07 2024-05-15 am EDT			5-day change	1st Jan Change
0.0025 ^USD	0.00%		+66.67%	+92.31%

2023	Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	CI
2023	Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	CI

HTG Molecular Diagnostics, Inc. Reports Preliminary Financial Results for the First Quarter Ended March 31, 2021 and Full Year 2021

April 05, 2021 at 04:03 pm EDT

HTG Molecular Diagnostics, Inc. reported preliminary financial results for the first quarter ended March 31, 2021. For the quarter, the company to expects to report unaudited total revenue of approximately $1.4 million. For the full year, the company expects its revenue could grow 30% to 40% .

Latest news about HTG Molecular Diagnostics, Inc.

Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	23-08-25	CI
Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	23-08-16	CI
Trustee/Examiner Appointed Under Chapter 11 for HTG Molecular Diagnostics, Inc.	23-07-21	CI
HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index	23-06-14	CI
HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index	23-06-08	CI
Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer	23-06-05	CI
HTG Molecular Diagnostics, Inc. Filed for Bankruptcy	23-06-05	CI
HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization	23-05-18	CI
Top Premarket Gainers	23-05-17	MT
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
HC Wainwright Adjusts Price Target on HTG Molecular Diagnostics to $6 From $15, Maintains Buy Rating	23-04-03	MT
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
HTG Molecular Diagnostics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Certain Warrants of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
Certain Restricted Stock Units of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
Certain Stock Options of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
Certain Common Stock of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event	23-01-09	CI
HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022	23-01-06	CI
China's Move to End COVID Quarantine for Inbound Travelers Sparks Premarket Gains for US Equities	22-12-27	MT
Top Premarket Gainers	22-12-27	MT
HTG Molecular Diagnostics to Begin Trading on Split-Adjusted Basis on Wednesday	22-12-20	MT
Transcript : HTG Molecular Diagnostics, Inc. - Special Call	22-12-13
Wall Street Set to Open Higher as Investors Await Inflation Data, Fed Rate Decision in Coming Days	22-12-12	MT
US Futures Move Modestly Higher Monday Ahead of Inflation Data Tuesday, Fed Rate Decision Meeting Conclusion Wednesday	22-12-12	MT

Chart HTG Molecular Diagnostics, Inc.

Duration

Period

More charts

Company Profile

HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.

Sector

Advanced Medical Equipment & Technology

Calendar

2025-05-07 - Q1 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
HTG MOLECULAR DIAGNOSTICS, INC.	+92.31%	5.54K
SARTORIUS AG	-18.97%	18.12B
QUIDELORTHO CORPORATION	-42.48%	2.87B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+22.69%	1.9B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-1.56%	1.65B
BIOTAGE AB	+32.98%	1.34B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-17.41%	957M
CONTEC MEDICAL SYSTEMS CO.,LTD	-22.25%	896M
REVENIO GROUP OYJ	+10.31%	841M
VAREX IMAGING CORPORATION	-26.78%	612M

Medical Diagnostic & Testing Equipment